AIM ImmunoTech Inc. (AIM)
| Market Cap | 3.69M -53.0% |
| Revenue (ttm) | 94,000 -35.6% |
| Net Income | -13.28M |
| EPS | -6.69 |
| Shares Out | 15.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,206,740 |
| Open | 0.2450 |
| Previous Close | 0.2435 |
| Day's Range | 0.2300 - 0.2480 |
| 52-Week Range | 0.2100 - 19.7180 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 5.75 (+2,353.07%) |
| Earnings Date | May 15, 2026 |
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also ... [Read more]
Financial Performance
In 2025, AIM ImmunoTech's revenue was $88,000, a decrease of -48.24% compared to the previous year's $170,000. Losses were -$13.96 million, -19.41% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AIM stock is "Buy." The 12-month stock price target is $5.75, which is an increase of 2,353.07% from the latest price.
News
AIM ImmunoTech Inc trading resumes
15:20 EDT AIM ImmunoTech (AIM) Inc trading resumes
AIM ImmunoTech announces $2.4M registered direct offering
AIM ImmunoTech (AIM) announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7.52M shares of common stock…
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct ...
AIM ImmunoTech Inc trading halted, news pending
14:57 EDT AIM ImmunoTech (AIM) Inc trading halted, news pending
CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework
SCHAUMBURG, Ill.--(BUSINESS WIRE)-- #isaca--CMMI Institute, a global leader in helping organizations reduce risk, boost performance, and build capability, is now extending this guidance to artificial ...
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
Increase in stockholder equity and note extension strengthen Company's ability to advance pancreatic cancer development strategy Increase in stockholder equity and note extension strengthen Company's ...
AIM ImmunoTech Quarterly report: Q1 2026
AIM ImmunoTech has published its Q1 2026 quarterly earnings report on May 15, 2026.
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon...
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of drug...
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin Final UPMC Primary Endpoint Report Details Positive Data fro...
AIM ImmunoTech Transcript: Virtual Investor Closing Bell
Ampligen’s focus on late-stage pancreatic cancer is driven by strong clinical data, significant unmet need, and robust market opportunity. The ongoing phase II DURIPANC study shows positive interim results, with phase III planning underway in partnership with Thermo Fisher Scientific. Orphan drug status and patent protection support long-term value and potential for major partnerships.
AIM ImmunoTech highlights accelerating momentum in pancreatic cancer program
AIM ImmunoTech (AIM) highlighted accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, Phase 2 clinical signals, and a strengthening global regulatory...
AIM ImmunoTech Provides Routine Update on Annual Filings
OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year e...
AIM ImmunoTech Annual report: Q4 2025
AIM ImmunoTech has published its Q4 2025 annual report on March 27, 2026.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: AIM ImmunoTech (AIM), 3,847.63% surge in interest Pipelin...
Why Is AIM ImmunoTech Stock (AIM) Up Today?
AIM ImmunoTech stock gained on Wednesday after it received patent approval for its cancer treatment in Japan.
AIM announces approval of patent for Ampligen in Japan
AIM ImmunoTech (AIM) announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s proprietary use of Ampligen in combination with checkpoint inhibitors for the tr...
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of panc...
AIM ImmunoTech Announces Closing of its Rights Offering
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and developmen...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: AIM Immunotech (AIM), 32.78% surge in interest Pipeline a...
AIM ImmunoTech announces preliminary results of rights offering
AIM ImmunoTech (AIM) announced the preliminary results of its previously announced rights offering which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights…
AIM ImmunoTech signs agreement for planning of Phase 3 trial of Ampligen
AIM ImmunoTech (AIM) announced an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design AIM’s anticipated Phase 3 clinical trial in the use of the…
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher...
AIM ImmunoTech reminds stockholders of expiration date for rights offering
AIM ImmunoTech (AIM) announced updated terms for its previously announced rights offering. Each subscription right now entitles holders to purchase one unit, each Unit consisting of one share of the…
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development...